Third Quarter and Year-to-Date 2024 Financial Results

IOVA 11.07.2024

Full Press ReleaseSEC FilingsOur IOVA Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  • 11.26.2024 - Iovance Biotherapeutics Announces the Promotion of Raj Puri, M.D., Ph.D. to Chief Regulatory Officer
  • 11.19.2024 - Stifel 2024 Healthcare Conference

Recent Filings

  • 01.16.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.13.2024 - S-8 Securities to be offered to employees in employee benefit plans
  • 12.02.2024 - 3 Initial statement of beneficial ownership of securities
Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com